Skip to main content
Click Here For COVID-19 Studies
Home
Clinical Trials Office Register as a Researcher Log In
348 Studies Now Enrolling
 Menu
Home How It Works Resources Join RecruitMe

Search

Reset

Status

  • Show all (4)
  • Currently Recruiting (1)
  • (-) Closed (3)

Medical Condition

  • Show all (103)
  • Allergy, Asthma, & Immunology (1)
  • All of Us Research Program - NIH (1)
  • Autoimmune Disorders (6)
  • Bone & Muscle (1)
  • Cancer (66)
  • COVID-19 (Coronavirus) (2)
  • Diabetes (1)
  • Hair and Skin Disorders (1)
  • Healthy Volunteers (5)
  • Heart Disease (3)
  • Kidney Disease (1)
  • Lung Disease (4)
  • (-) Neurological Disorders (3)
    • Brain Tumors (1)
    • Neuropathy (1)
  • Obstetrics & Gynecology (2)
  • Pediatrics (2)
  • Psychiatric Disorders (1)
  • Transplant (2)
  • Vascular Conditions (1)
Displaying 1 - 3 of 3

Study of Vismodegib and GSK2256098 to Shrink Tumors in Patients with Meningioma

Condition: Neurological Disorders / Brain Tumors
Investigator: Mary Welch, MD
Status: Closed
The purpose of this study is to test good and bad effects of these two different drugs against meningioma tumors with altered genes. Today, therapy for meningioma is the same for all patients and is not based on tumor genetic testing. This trial is trying to see if tumor genetic testing would be helpful at guiding treatment in patients with meningioma.…
Read More

A study for patients with Parkinson's Disease using study drug Levodopa (APL-130277)

Condition: Neurological Disorders
Investigator: Cheryl Waters, MD
Status: Closed
The purpose of this study is to test the effectiveness of investigational drug APL-130277 for patients with Parkinson's disease. APL-130277 is an investigational drug, which means that the study drug is currently being tested. It is not approved by the U.S. Food and Drug Administration (FDA). The active ingredient in APL-130277 is apomorphine, a medication…
Read More

Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) and Treatment with Subcutaneous Immunoglobulin

Condition: Neurological Disorders / Neuropathy
Investigator: Thomas Brannagan, MD
Status: Closed
The purpose of this study is to see how effective two doses of an investigational new drug called IgPro20 is when given subcutaneously (a shot given into the fat layer between the skin and the muscle) to treat CIDP in patients that still require IVIG and also to look at how safe the IgPro20 is for patients.
Read More
This website uses cookies as well as similar tools and technologies to understand visitors’ experiences. By continuing to use this website, you consent to Columbia University’s usage of cookies and similar technologies, in accordance with the Columbia University Website Cookie Notice.
I AGREE
COMPLIANCE
Compliance Hotline Compliance Program
RESOURCES
Contact RecruitMe Terms of Use Privacy Policy ©2025 Columbia University
SCHOOLS
Vagelos College of Physicians and Surgeons Mailman School of Public Health School of Nursing College of Dental Medicine Graduate School of Arts and Science